Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of “Hold” by Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been given a consensus recommendation of “Hold” by the fourteen brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $15.55.

Several equities analysts have commented on FOLD shares. The Goldman Sachs Group upped their price objective on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. TD Cowen cut Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price objective for the company. in a report on Monday, December 22nd. Finally, Guggenheim downgraded Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th.

Insider Transactions at Amicus Therapeutics

In related news, insider Jeff Castelli sold 76,158 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $10.16, for a total value of $773,765.28. Following the transaction, the insider directly owned 439,318 shares in the company, valued at approximately $4,463,470.88. This represents a 14.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David Michael Clark sold 25,643 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $10.10, for a total transaction of $258,994.30. Following the transaction, the insider directly owned 296,975 shares in the company, valued at approximately $2,999,447.50. This represents a 7.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 394,807 shares of company stock valued at $4,486,385. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. HBK Investments L P bought a new stake in shares of Amicus Therapeutics in the fourth quarter valued at approximately $217,160,000. Pentwater Capital Management LP acquired a new position in Amicus Therapeutics in the 4th quarter valued at $163,760,000. Vestal Point Capital LP lifted its position in shares of Amicus Therapeutics by 178.4% during the 2nd quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock valued at $68,187,000 after acquiring an additional 7,625,000 shares during the period. Soros Fund Management LLC acquired a new stake in shares of Amicus Therapeutics during the 4th quarter worth $71,200,000. Finally, UBS Group AG grew its holdings in shares of Amicus Therapeutics by 240.5% during the 4th quarter. UBS Group AG now owns 5,893,288 shares of the biopharmaceutical company’s stock worth $83,920,000 after purchasing an additional 4,162,433 shares in the last quarter.

Amicus Therapeutics Stock Performance

FOLD opened at $14.34 on Thursday. The company has a quick ratio of 2.09, a current ratio of 2.99 and a debt-to-equity ratio of 1.70. Amicus Therapeutics has a 12-month low of $5.51 and a 12-month high of $14.38. The business has a 50 day moving average of $13.85 and a 200-day moving average of $10.32. The stock has a market cap of $4.50 billion, a price-to-earnings ratio of -358.41 and a beta of 0.38.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.